Altimmune (ALT) Short Interest Ratio & Short Volume $3.83 +0.12 (+3.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.79 -0.04 (-1.15%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Altimmune Short Interest DataAltimmune (ALT) has a short interest of 25.76 million shares, representing 33.12% of the float (the number of shares available for trading by the public). This marks a -8.33% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.6, indicating that it would take 4.6 days of the average trading volume of 2.97 million shares to cover all short positions.Current Short Interest25,760,000 sharesPrevious Short Interest28,100,000 sharesChange Vs. Previous Month-8.33%Dollar Volume Sold Short$95.05 millionShort Interest Ratio4.6 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares88,260,000 sharesShort Percent of Float33.12%Today's Trading Volume2,739,803 sharesAverage Trading Volume2,972,399 sharesToday's Volume Vs. Average92% Short Selling Altimmune? Sign up to receive the latest short interest report for Altimmune and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALT Short Interest Over TimeALT Days to Cover Over TimeALT Percentage of Float Shorted Over Time Altimmune Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202525,760,000 shares $95.05 million -8.3%33.1%4.6 $3.69 7/15/202528,100,000 shares $117.46 million -9.9%N/A5.1 $4.18 6/30/202531,180,000 shares $120.67 million +27.8%40.1%5.9 $3.87 6/15/202524,400,000 shares $168.85 million +11.0%31.4%8.6 $6.92 5/31/202521,980,000 shares $119.35 million -3.0%32.2%8.4 $5.43 5/15/202522,670,000 shares $131.03 million +0.4%33.2%8.8 $5.78 4/30/202522,580,000 shares $118.55 million +0.6%N/A8.9 $5.25 4/15/202522,440,000 shares $101.65 million +2.8%32.9%9.2 $4.53 3/31/202521,820,000 shares $109.10 million -2.8%32.0%8.5 $5.00 3/15/202522,450,000 shares $132.90 million +3.6%32.9%8.6 $5.92 Get the Latest News and Ratings for ALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. 2/28/202521,670,000 shares $144.11 million -3.6%31.8%8.2 $6.65 2/15/202522,470,000 shares $143.13 million -3.6%32.9%8.6 $6.37 1/31/202523,320,000 shares $154.84 million -5.2%N/A7.3 $6.64 1/15/202524,590,000 shares $161.80 million +3.8%N/A7.7 $6.58 12/31/202423,690,000 shares $170.80 million -0.7%N/A7.5 $7.21 12/15/202423,850,000 shares $215.37 million +1.8%N/A7.8 $9.03 11/30/202423,430,000 shares $200.80 million +2.6%N/A7.7 $8.57 11/15/202422,840,000 shares $173.81 million -0.4%N/A8.4 $7.61 10/31/202422,940,000 shares $154.62 million +3.2%N/A10.6 $6.74 10/15/202422,230,000 shares $156.50 million -0.8%N/A10.1 $7.04 9/30/202422,400,000 shares $137.54 million +2.4%N/A9.3 $6.14 9/15/202421,870,000 shares $172.34 million -0.6%N/A6.9 $7.88 8/31/202422,000,000 shares $147.40 million +1.4%N/A6.7 $6.70 8/15/202421,700,000 shares $135.41 million -2.4%N/A6.5 $6.24 7/31/202422,240,000 shares $141.45 million -1.6%N/A6.3 $6.36 7/15/202422,610,000 shares $178.62 million +1.7%N/A6.4 $7.90 6/30/202422,240,000 shares $147.90 million -3.9%N/A6.2 $6.65 6/15/202423,140,000 shares $141.39 million -1.4%N/A6.5 $6.11 5/31/202423,470,000 shares $176.26 million +1.8%N/A7 $7.51 5/15/202423,060,000 shares $204.54 million +3.4%N/A5.5 $8.87 4/30/202422,310,000 shares $146.13 million +9.5%N/A4.9 $6.55 4/15/202420,370,000 shares $153.79 million +14.9%N/A4.3 $7.55 3/31/202417,730,000 shares $180.49 million +41.7%N/A3.2 $10.18 3/15/202412,510,000 shares $123.35 million +15.7%N/A1.9 $9.86 2/29/202410,810,000 shares $130.80 million -6.4%N/A1.1 $12.10 2/15/202411,550,000 shares $103.37 million +15.4%N/A1 $8.95 1/31/202410,010,000 shares $94.49 million -6.1%N/A0.9 $9.44 1/15/202410,660,000 shares $127.92 million +12.9%N/A1 $12.00 12/31/20239,440,000 shares $106.20 million -14.9%N/A1 $11.25 12/15/202311,090,000 shares $85.06 million +71.9%N/A1.3 $7.67[No Brainer Gold Play]: “Show me a better investment.” (Ad)A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Click here to get Garrett’s Top Four picks now. 11/30/20236,450,000 shares $20.38 million -4.2%N/A1 $3.16 11/15/20236,730,000 shares $16.42 million -1.9%N/A5.8 $2.44 10/31/20236,860,000 shares $16.53 million -7.3%N/A5.9 $2.41 10/15/20237,400,000 shares $19.68 million +3.5%N/A6.9 $2.66 9/30/20237,150,000 shares $18.59 million +9.3%N/A6.5 $2.60 9/15/20236,540,000 shares $19.10 million +8.5%N/A5.3 $2.92 8/31/20236,030,000 shares $15.26 million +4.3%N/A3.7 $2.53 8/15/20235,780,000 shares $16.24 million -6.2%N/A3.3 $2.81 7/31/20236,160,000 shares $20.39 million -16.2%N/A3.4 $3.31 7/15/20237,350,000 shares $24.11 million +5.6%N/A4.1 $3.28 6/30/20236,960,000 shares $24.57 million -23.8%N/A3.6 $3.53 6/15/20239,130,000 shares $37.34 million +0.6%N/A4.3 $4.09 5/31/20239,080,000 shares $36.68 million +2.6%N/A4.2 $4.04 5/15/20238,850,000 shares $42.92 million -2.1%N/A4.3 $4.85 4/30/20239,040,000 shares $45.65 million -8.3%N/A4.5 $5.05 4/15/20239,860,000 shares $47.13 million +3.8%N/A4.8 $4.78 3/31/20239,500,000 shares $40.09 million +28.4%N/A4.9 $4.22 3/15/20237,400,000 shares $80.88 million +16.0%N/A3.9 $10.93 2/28/20236,380,000 shares $80.32 million +1.9%N/A4.6 $12.59 2/15/20236,260,000 shares $75.06 million +1.5%N/A4.5 $11.99 1/31/20236,170,000 shares $84.16 million -15.7%N/A4.3 $13.64 1/15/20237,320,000 shares $119.24 million -3.4%N/A5.3 $16.29 12/30/20227,580,000 shares $124.69 million +19.6%N/A5.6 $16.45 12/15/20226,340,000 shares $66.38 million -3.4%N/A4.5 $10.47 11/30/20226,560,000 shares $65.27 million -10.0%N/A2.9 $9.95 11/15/20227,290,000 shares $79.61 million +1.8%N/A3.2 $10.92 10/31/20227,160,000 shares $89.79 million +1.6%N/A2.9 $12.54 10/15/20227,050,000 shares $73.32 million -8.4%N/A2.9 $10.40 9/30/20227,700,000 shares $98.33 million +13.9%N/A3.1 $12.77 9/15/20226,760,000 shares $97.28 million +9.7%N/A2.6 $14.39 8/31/20226,160,000 shares $136.01 million +26.8%N/A3.3 $22.08 8/15/20224,860,000 shares $85.24 million No ChangeN/A2.9 $17.54 7/31/20224,860,000 shares $58.37 million +10.5%N/A3.2 $12.01 7/15/20224,400,000 shares $49.85 million -26.3%N/A3.1 $11.33 6/30/20225,970,000 shares $69.85 million -3.1%N/A4.5 $11.70 6/15/20226,160,000 shares $51.25 million +56.4%N/A5.4 $8.32 5/31/20223,940,000 shares $19.94 million +2.3%N/A4.7 $5.06 5/15/20223,850,000 shares $19.87 million +27.5%N/A4.5 $5.16 4/30/20223,020,000 shares $13.65 million +6.3%N/A3.6 $4.52 4/15/20222,840,000 shares $14.85 million +7.6%N/A3.3 $5.23 3/31/20222,640,000 shares $16.08 million -36.2%N/A3.2 $6.09 3/15/20224,140,000 shares $24.43 million +5.1%N/A4.8 $5.90 2/28/20223,940,000 shares $29.20 million +9.4%10.5%5.4 $7.41 2/15/20223,600,000 shares $28.58 million +6.8%9.6%5 $7.94 1/31/20223,370,000 shares $27.20 million -26.4%10.0%4.4 $8.07 1/15/20224,580,000 shares $35.91 million +2.0%13.6%6.2 $7.84 12/31/20214,490,000 shares $41.13 million +4.7%13.4%6 $9.16 12/15/20214,290,000 shares $38.95 million -0.5%12.8%4 $9.08 11/30/20214,310,000 shares $45.21 million -9.5%12.8%3.8 $10.49 11/15/20214,760,000 shares $53.12 million -15.2%14.2%3.8 $11.16[No Brainer Gold Play]: “Show me a better investment.” (Ad)A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Click here to get Garrett’s Top Four picks now. 10/29/20215,610,000 shares $60.59 million -1.9%16.6%4.2 $10.80 10/15/20215,720,000 shares $68.70 million -6.7%16.9%4.3 $12.01 9/30/20216,130,000 shares $69.33 million -7.8%18.1%4.5 $11.31 9/15/20216,650,000 shares $109.92 million +4.2%19.7%4.1 $16.53 8/31/20216,380,000 shares $95.64 million +21.5%18.9%3.2 $14.99 8/13/20215,250,000 shares $63.11 million +5.0%15.5%2.7 $12.02 7/30/20215,000,000 shares $45.35 million -4.9%15.4%2.7 $9.07 7/15/20215,260,000 shares $45.34 million +13.4%16.2%2.8 $8.62 6/30/20214,640,000 shares $45.70 million +10.2%14.3%2.4 $9.85 6/15/20214,210,000 shares $59.49 million -0.5%13.0%3.2 $14.13 5/28/20214,230,000 shares $53.51 million -19.6%13.0%3.8 $12.65 5/14/20215,260,000 shares $67.01 million +4.2%N/A4.4 $12.74 4/30/20215,050,000 shares $71.81 million +4.3%N/A3.8 $14.22 4/15/20214,840,000 shares $62.68 million -10.7%N/A3.1 $12.95 3/31/20215,420,000 shares $73.44 million +82.5%N/A3.4 $13.55 3/15/20212,970,000 shares $49.78 million +23.2%N/A1.7 $16.76 2/26/20212,410,000 shares $41.45 million -4.4%N/A1.4 $17.20 2/12/20212,520,000 shares $55.64 million -3.5%N/A1.3 $22.08 1/29/20212,610,000 shares $35.10 million +0.4%N/A1.3 $13.45 1/15/20212,600,000 shares $35.28 million -11.3%N/A1.5 $13.57 12/31/20202,930,000 shares $33.11 million +17.7%N/A1.5 $11.30 12/15/20202,490,000 shares $33.22 million +14.2%N/A1.4 $13.34 11/30/20202,180,000 shares $22.93 million -9.9%N/A1.2 $10.52 11/15/20202,420,000 shares $24.51 million -16.8%N/A1.5 $10.13 10/30/20202,910,000 shares $33.26 million +25.4%N/A1.8 $11.43 10/15/20202,320,000 shares $29.70 million +11.5%N/A1.3 $12.80 9/30/20202,080,000 shares $27.46 million +41.5%N/A0.8 $13.20 9/15/20201,470,000 shares $18.30 million +44.1%N/A0.4 $12.45 ALT Short Interest - Frequently Asked Questions What is Altimmune's current short interest? Short interest is the volume of Altimmune shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 25,760,000 shares of ALT short. 33.12% of Altimmune's shares are currently sold short. Learn More on Altimmune's current short interest. What is a good short interest ratio for Altimmune? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALT shares currently have a short interest ratio of 5.0. Learn More on Altimmune's short interest ratio. Which institutional investors are shorting Altimmune? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Altimmune: Exome Asset Management LLC, Sculptor Capital LP, LMR Partners LLP, Group One Trading LLC, Jane Street Group LLC, Caption Management LLC, Diadema Partners LP, Walleye Capital LLC, Walleye Trading LLC, DLD Asset Management LP, JPMorgan Chase & Co., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Altimmune? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 33.12% of Altimmune's floating shares are currently sold short. Is Altimmune's short interest increasing or decreasing? Altimmune saw a decrease in short interest in July. As of July 31st, there was short interest totaling 25,760,000 shares, a decrease of 8.3% from the previous total of 28,100,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Altimmune's short interest compare to its competitors? 33.12% of Altimmune's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Altimmune: Precigen, Inc. (19.71%), Enliven Therapeutics, Inc. (12.93%), LENZ Therapeutics, Inc. (16.64%), Zymeworks Inc. (3.24%), Arcus Biosciences, Inc. (13.81%), Structure Therapeutics Inc. Sponsored ADR (13.14%), Stoke Therapeutics, Inc. (23.13%), CorMedix Inc (15.11%), atai Life Sciences N.V. (11.56%), Spyre Therapeutics, Inc. (25.08%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Altimmune stock? Short selling ALT is an investing strategy that aims to generate trading profit from Altimmune as its price is falling. ALT shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Altimmune? A short squeeze for Altimmune occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALT, which in turn drives the price of the stock up even further. How often is Altimmune's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALT, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies PGEN Short Squeeze ELVN Short Squeeze LENZ Short Squeeze ZYME Short Squeeze RCUS Short Squeeze GPCR Short Squeeze STOK Short Squeeze CRMD Short Squeeze ATAI Short Squeeze SYRE Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALT) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts